ArticleHistopathology2025
Renal cell carcinoma with fibromyomatous stroma (RCC FMS) and with hemangioblastoma-like areas is part of the RCC FMS spectrum in patients with tuberous sclerosis complex.
Article in Histopathology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Does renal haemangioblastoma exist? Evidence for inclusion within the MTOR-associated renal cell carcinoma with fibromyomatous stroma spectrum.Histopathology · 2026Article
- Renal cell carcinoma with fibromyomatous stroma and renal hemangioblastoma represent a continuum of one tumor spectrum: a comprehensive, critical review of the literature.Virchows Archiv : an international journal of pathology · 2026Review
- Immunohistochemical expression of GPNMB in TFEB-rearranged and TFEB-amplified renal cell carcinomas.Virchows Archiv : an international journal of pathology · 2026Article
- Recurrent mTOR pathway alterations in renal cell carcinoma with hemangioblastoma-like features: A multi-institutional study of 9 cases with expanding morphologic spectrum.Virchows Archiv : an international journal of pathology · 2026Article
- Renal hemangioblastoma and renal cell carcinoma with fibromyomatous stroma and hemangioblastoma-like areas belong to the spectrum of one entity.Virchows Archiv : an international journal of pathology · 2026Article
- Hemangioblastoma of the Kidney-A Comprehensive Clinical, Pathological, and Genetic Analysis of Four Cases.APMIS : acta pathologica, microbiologica, et immunologica Scandinavica · 2026Article
- Renal Cell Carcinoma With Hemangioblastoma-Like Features, Fibromyomatous Stroma, and TSC1 Mutation.Case reports in medicine · 2026Article
- Bilateral synchronous papillary renal neoplasm with reverse polarity and renal cell carcinoma with fibromyomatous stroma: a case report and review of the literature.Frontiers in oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsSporadic renal cell carcinomas with fibromyomatous stroma (RCC FMS) with coexistent haemangioblastoma (HB)-like morphology have been previously reported. Such morphology has not, however, been documented in patients with tuberous sclerosis complex (TSC). We evaluated clinicopathologic, immunohistochemical and molecular findings of RCC FMS with HB-like features in three TSC patients. METHODS AND
resultsAll three patients were females with confirmed germline mutations in TSC1 in the absence of VHL or other alterations. One patient had bilateral nephrectomy with six separate tumours (three in each kidney), and two patients had one tumour each, resected by partial nephrectomy. Prominent fibromuscular stroma was present at the tumoral periphery and surrounding clear cell nests forming tubules and papillary formations (RCC FMS areas), admixed with solid, clear to eosinophilic and spindle cell areas (HB-like areas). HB-like areas were variably represented in individual tumours, but in some, HB-like features were almost exclusive. HB-like areas were negative for CK7 and showed inhibin-α and S100 reactivity, in contrast to typical RCC FMS areas, which were CK7 positive, while negative for inhibin-α and S100. GPNMB, which is consistently expressed in TSC/mTOR altered tumours, was positive in both components. On follow-up (10 months-21 years), all patients had an indolent course.
conclusionsHB-like morphology found in RCC FMS in TSC patients represents part of the morphologic spectrum of RCC FMS, which is a previously underreported and underrecognized feature. RCC FMS with HB-like areas show uniform GPNMB reactivity and are associated with TSC/MTOR alterations, but not with VHL alterations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.